Elevated Prostate Health Index (phi) and Biopsy Reclassification During Active Surveillance of Prostate Cancer

Darian Andreas, Jeffrey J. Tosoian*, Patricia Landis, Sacha Wolf, Stephanie Glavaris, Tamara L. Lotan, Edward M. Schaeffer, Lori J. Sokoll, Ashley E. Ross

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

2 Scopus citations

Abstract

The Prostate Health Index (phi) has been FDA approved for decision-making regarding prostate biopsy. Phi has additionally been shown to positively correlate with tumor volume, extraprostatic disease and higher Gleason grade tumors. Here we describe a case in which an elevated phi encouraged biopsy of a gentleman undergoing active surveillance leading to reclassification of his disease as high risk prostate cancer.

Original languageEnglish (US)
Pages (from-to)64-66
Number of pages3
JournalUrology Case Reports
Volume7
DOIs
StatePublished - Jul 1 2016

Keywords

  • Active surveillance
  • Biomarkers
  • Prostate biopsy
  • Prostate cancer

ASJC Scopus subject areas

  • Urology

Fingerprint

Dive into the research topics of 'Elevated Prostate Health Index (phi) and Biopsy Reclassification During Active Surveillance of Prostate Cancer'. Together they form a unique fingerprint.

Cite this